Results of the April 2017 CCS-Quebec Division/Mont Gabriel Summit Research Fund (Cole Foundation) Grants competition

We are pleased to announce the results of the CCS-Quebec Division/Mont Gabriel Summit Research Fund (Cole Foundation) Grants competition. This program is a partnership between the CCS Quebec Division and the Cole Foundation and its partners, to fund research grants in the area of pediatric and young adult leukemia and lymphoma research. Below is a listing of the newly awarded grants.

4 CCS-Quebec Division/Mont Gabriel Summit Research Fund (Cole Foundation) Grants have been approved – 27% of all proposals received. Grants are valued at up to $750,000 over a 3-year term. These 4 new grants represent an investment of almost $2.8 million.

Significant contributors to the Cole Foundation Fund are: the Molson Foundation, the R. Howard Webster Foundation, Mirella & Lino Saputo Foundation, Birks Family Foundation, Letko Brosseau – WCPD Foundation, Université de Montréal, Trottier Foundation, Maryse & William Brock Chair, Power Corp, Fondation CHU Sainte Justine, the Montreal Children’s Hospital Foundation, Morris & Rosalind Goodman Family Foundation, the Zeller Family Foundation, Drummond Foundation, the David Laidley Foundation and the Henry & Berenice Kaufmann Foundation.

Funded Grant Summaries

Please note: 

  • Amounts listed below represent the total dollars awarded by grant year and may include funds for salaries, supplies, and/or equipment.
  • The start date for these grants is February 1, 2018.
  • Only the Principal Investigator is named in this listing. Co-Principal Investigators, Co-Applicants and/or Additional Authors may also be associated with these grants.

Note Carefully:

Although every effort has been made to ensure the accuracy of the listing below, this list does not constitute an "official" notification.

Successful applicants will be informed, in writing, with an official Notification of Award giving the details pertaining to their grant.

Haddad, Elie
Hôpital Sainte Justine
Chimeric Antigen Receptor (CAR) therapy in hematopoietic stem cells: an innovative treatment strategy in lymphoblastic leukemia
2018/2019 :  $249,368
2019/2020 :  $249,362
2020/2021 :  $249,480
Johnson, Nathalie
Jewish General Hospital
Optimizing immunotherapy in high risk adolescent and young adult (AYA) lymphomas
2018/2019 :  $175,297
2019/2020 :  $175,297
2020/2021 :  $175,296
Mallette, Frederick
Hôpital Maisonneuve Rosemont
Identification of therapeutic targets for pediatric acute megakaryoblastic leukemia
2018/2019 :  $250,000
2019/2020 :  $250,000
2020/2021 :  $250,000
Sauvageau, Guy
Université de Montréal
RUNX1 mutation sensitizes human AML to H3K27 hypomethylation: a step towards precision therapy
2018/2019 :  $250,000
2019/2020 :  $250,000
2020/2021 :  $245,613

Last modified on: January 23, 2018